Shell Asset Management CO 2seventy Bio, Inc. Transaction History

Shell Asset Management CO

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 08, 2023	BUY	$3.14 - $11.2 $125,279 - $446,857	39,898 Added 879.2%	44,436 $174,000
Q2 2023 Jul 28, 2023	SELL	$8.45 - $12.48 $202 - $299	-24 Reduced 0.53%	4,538 $46,000
Q1 2023 May 15, 2023	SELL	$9.21 - $14.98 $156 - $254	-17 Reduced 0.37%	4,562 $47,000
Q4 2022 Feb 07, 2023	SELL	$8.57 - $17.0 $4,807 - $9,537	-561 Reduced 10.91%	4,579 $43,000
Q3 2022 Nov 14, 2022	SELL	$12.56 - $17.54 $8,377 - $11,699	-667 Reduced 11.49%	5,140 $75,000
Q2 2022 Aug 09, 2022	BUY	$10.55 - $18.81 $875 - $1,561	83 Added 1.45%	5,807 $77,000
Q1 2022 May 04, 2022	SELL	$11.67 - $26.72 $9,826 - $22,498	-842 Reduced 12.82%	5,724 $98,000
Q4 2021 Feb 09, 2022	BUY	$13.77 - $42.56 $90,413 - $279,448	6,566 New	6,566 $168,000

126

45.6M

122K

19.8K

Ticker TSVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,873,600
Market Cap $113M
Description
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a col...

Get notified when there are updates to the investment portfolio of Shell Asset Management CO, based on Form 13F filings with the SEC.

Stay updated on Shell Asset Management CO with notifications on news.